search icon
rigl-img

Rigel Pharmaceuticals Inc, Common Stock

RIGL

NSQ

$19.125

-$0.41

(-2.1%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$352.62M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
9.169
Volume info-icon
This is the total number of shares traded during the most recent trading day.
80.79K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.33
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$7.48 L
$29.82 H
$19.125

About Rigel Pharmaceuticals Inc, Common Stock

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameRIGLSectorS&P500
1-Week Return-1.01%1.39%1.18%
1-Month Return-0.2%-4.97%6.44%
3-Month Return-15.31%-11.13%-0.73%
6-Month Return-29.26%-10.21%-2.01%
1-Year Return112.88%-6.5%12.12%
3-Year Return7.9%0.1%42.84%
5-Year Return-0.1%28.49%93.86%
10-Year Return-44.04%76.62%180.28%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue108.62M149.24M120.24M116.88M179.28M[{"date":"2020-12-31","value":60.59,"profit":true},{"date":"2021-12-31","value":83.24,"profit":true},{"date":"2022-12-31","value":67.07,"profit":true},{"date":"2023-12-31","value":65.2,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue895.00K1.08M1.75M7.11M18.65M[{"date":"2020-12-31","value":4.8,"profit":true},{"date":"2021-12-31","value":5.81,"profit":true},{"date":"2022-12-31","value":9.38,"profit":true},{"date":"2023-12-31","value":38.13,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit107.73M148.15M118.49M109.77M160.63M[{"date":"2020-12-31","value":67.06,"profit":true},{"date":"2021-12-31","value":92.23,"profit":true},{"date":"2022-12-31","value":73.77,"profit":true},{"date":"2023-12-31","value":68.34,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin99.18%99.27%98.55%93.92%89.60%[{"date":"2020-12-31","value":99.9,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.27,"profit":true},{"date":"2023-12-31","value":94.6,"profit":true},{"date":"2024-12-31","value":90.25,"profit":true}]
Operating Expenses136.70M157.13M172.72M130.26M136.44M[{"date":"2020-12-31","value":79.14,"profit":true},{"date":"2021-12-31","value":90.97,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":75.42,"profit":true},{"date":"2024-12-31","value":78.99,"profit":true}]
Operating Income(28.97M)(8.97M)(54.23M)(20.49M)24.19M[{"date":"2020-12-31","value":-119.76,"profit":false},{"date":"2021-12-31","value":-37.1,"profit":false},{"date":"2022-12-31","value":-224.17,"profit":false},{"date":"2023-12-31","value":-84.7,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(1.54M)(9.63M)(6.05M)(8.65M)(11.65M)[{"date":"2020-12-31","value":-154200000,"profit":false},{"date":"2021-12-31","value":-962600000,"profit":false},{"date":"2022-12-31","value":-604600000,"profit":false},{"date":"2023-12-31","value":-864900000,"profit":false},{"date":"2024-12-31","value":-1165200000,"profit":false}]
Pre-Tax Income(29.74M)(17.31M)(58.57M)(25.09M)18.37M[{"date":"2020-12-31","value":-161.95,"profit":false},{"date":"2021-12-31","value":-94.24,"profit":false},{"date":"2022-12-31","value":-318.92,"profit":false},{"date":"2023-12-31","value":-136.62,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income Taxes647.00K605.00K3.02M2.27M881.00K[{"date":"2020-12-31","value":21.4,"profit":true},{"date":"2021-12-31","value":20.01,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":75.16,"profit":true},{"date":"2024-12-31","value":29.14,"profit":true}]
Income After Taxes(30.39M)(17.91M)(61.60M)(27.36M)17.48M[{"date":"2020-12-31","value":-173.81,"profit":false},{"date":"2021-12-31","value":-102.45,"profit":false},{"date":"2022-12-31","value":-352.28,"profit":false},{"date":"2023-12-31","value":-156.49,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income From Continuous Operations(29.74M)(17.91M)(58.57M)(24.43M)17.48M[{"date":"2020-12-31","value":-170.11,"profit":false},{"date":"2021-12-31","value":-102.45,"profit":false},{"date":"2022-12-31","value":-334.99,"profit":false},{"date":"2023-12-31","value":-139.7,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(30.39M)(17.91M)(61.60M)(25.09M)17.48M[{"date":"2020-12-31","value":-173.81,"profit":false},{"date":"2021-12-31","value":-102.45,"profit":false},{"date":"2022-12-31","value":-352.28,"profit":false},{"date":"2023-12-31","value":-143.5,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
EPS (Diluted)(0.16)(0.11)(0.34)(0.15)1.39[{"date":"2020-12-31","value":-11.51,"profit":false},{"date":"2021-12-31","value":-7.91,"profit":false},{"date":"2022-12-31","value":-24.46,"profit":false},{"date":"2023-12-31","value":-10.49,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RIGL
Cash Ratio 1.16
Current Ratio 2.20
Quick Ratio 2.13

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RIGL
ROA (LTM) 18.15%
ROE (LTM) -699.05%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RIGL
Debt Ratio Lower is generally better. Negative is bad. 0.89
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.11

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RIGL
Trailing PE 9.17
Forward PE 5.85
P/S (TTM) 1.72
P/B 18.47
Price/FCF NM
EV/R 1.61
EV/Ebitda 6.75
PEG NM

FAQs

What is Rigel Pharmaceuticals Inc share price today?

Rigel Pharmaceuticals Inc (RIGL) share price today is $19.125

Can Indians buy Rigel Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Rigel Pharmaceuticals Inc (RIGL) on Vested. To buy Rigel Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RIGL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Rigel Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Rigel Pharmaceuticals Inc (RIGL) via the Vested app. You can start investing in Rigel Pharmaceuticals Inc (RIGL) with a minimum investment of $1.

How to invest in Rigel Pharmaceuticals Inc shares from India?

You can invest in shares of Rigel Pharmaceuticals Inc (RIGL) via Vested in three simple steps:

  • Click on Sign Up or Invest in RIGL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Rigel Pharmaceuticals Inc shares
What is Rigel Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Rigel Pharmaceuticals Inc (RIGL) is $29.82. The 52-week low price of Rigel Pharmaceuticals Inc (RIGL) is $7.48.

What is Rigel Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Rigel Pharmaceuticals Inc (RIGL) is 9.169

What is Rigel Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Rigel Pharmaceuticals Inc (RIGL) is 18.47

What is the Market Cap of Rigel Pharmaceuticals Inc?

The market capitalization of Rigel Pharmaceuticals Inc (RIGL) is $352.62M

What is Rigel Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Rigel Pharmaceuticals Inc is RIGL

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top